Gupta J K, Johnson N
University Department of Obstetrics and Gynaecology, St James's University Hospital, Leeds, England.
Contraception. 1992 Nov;46(5):489-97. doi: 10.1016/0010-7824(92)90152-j.
Sixty-four women requesting first trimester termination of pregnancy were recruited into a comparative cohort study comparing the cervical ripening properties of a mechanical dilator (Lamicel; n = 17), prostaglandin, antiprogesterone and placebo control (n = 15), gemeprost; n = 17) and mifepristone; n = 15). Compared to the placebo group, all 3 active agents dilated the cervix (p < 0.02) and they significantly reduced the force required to dilate it to 8 mm Hegar (p < 0.001). Although Lamicel insertion resulted in the largest pre-operative cervical dilatation all agents are effective. Therefore the cervical priming agent of choice should be the most convenient to use and the one with least side-effects. The oral antiprogesterone, Mifepristone, is the easiest to administer and has less side effects.
64名要求在孕早期终止妊娠的女性被纳入一项比较队列研究，该研究比较了一种机械扩张器（Lamicel；n = 17）、前列腺素、抗孕激素和安慰剂对照组（n = 15）、米索前列醇（n = 17）和米非司酮（n = 15）的宫颈成熟特性。与安慰剂组相比，所有3种活性剂均能扩张宫颈（p < 0.02），并且它们显著降低了将宫颈扩张至8号Hegar扩张器所需的力量（p < 0.001）。尽管插入Lamicel导致术前宫颈扩张最大，但所有药物均有效。因此，首选的宫颈预处理药物应该是使用最方便且副作用最小的药物。口服抗孕激素米非司酮最易于给药且副作用较少。
